Extended Most-Favored-Nation Pricing to Mid-Sized Pharma

The U.S. White House has reached pricing agreements with nine companies, including Alcon, Astellas, BeiGene, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, and UCB. These companies are participating in CMS's six-year temporary GENEROUS model, aligning some Medicare drug prices with the lowest net prices in advanced foreign countries, in exchange for exemption from Section 232 tariffs under the Trade Expansion Act. State participation is voluntary, and product selection is at the state level, making the structure different from nationwide price reductions. Manufacturers will pay quarterly supplemental rebates tied to international net prices, reducing the burden of state-specific rebate negotiations.

Key Exposed Drugs Already on the Market

BridgeBio's marketed drug Attruby (acoramidis), a transthyretin (TTR) stabilizer, received FDA approval on November 22, 2024, for reducing cardiovascular death and hospitalization in adult ATTR cardiomyopathy. The standard competitor is Pfizer's (PFE) Vyndaqel/Vyndamax (tafamidis, TTR stabilizer), and Attruby's 2025 net sales were USD 362.4 million. BeiGene's marketed oncology drug Tevimbra (tislelizumab-jsgr), a PD-1 blocking antibody, first received U.S. approval on March 13, 2024, for the treatment of unresectable or metastatic esophageal squamous cell carcinoma as a subsequent therapy. Its approval was later expanded to gastric and gastroesophageal junction cancers and first-line esophageal cancer, with 2025 global sales reaching USD 737 million.

Revenue Impact is Limited but Product-Specific

Medicare spent USD 54 billion on brand-name drugs in 2024, but this is significantly smaller than the USD 163 billion spent on Medicare Part D prescriptions and already subject to statutory rebates. Medicare accounts for less than 2% of Attruby's sales, so the price linkage is not expected to significantly harm BridgeBio's profitability. Similarly, Tevimbra's Medicare discount impact is minimal, and BeiGene's key hematologic oncology product Brukinsa (zanubrutinib, BTK inhibitor) was excluded from the agreement. Given Brukinsa's 2025 global sales of USD 3.9 billion, BeiGene's primary cash-generating asset remains protected.

Regulatory Risks and Commercial Trade-Offs

Tevimbra competes in the first-line PD-1 gastric cancer market with Merck's (MRK) Keytruda (pembrolizumab) and Bristol Myers Squibb's (BMY) Opdivo (nivolumab). On September 26, 2024, the FDA advisory committee voted 10 to 2 with one abstention, concluding that the risk-benefit profile of PD-1 inhibitors in HER2-negative gastric and gastroesophageal junction cancers with PD-L1 expression less than 1 is unfavorable. As a result, Tevimbra's approval was limited to PD-L1 expression of 1 or higher. This agreement is not a cash upfront, milestone, or royalty deal, but a policy contract exchanging lowest-price provision, tariff exemption, U.S. production expansion, and raw material drug stockpiling. The removal of Section 232 tariffs and increased visibility of drug price regulation are more significant value drivers for participating companies than short-term profit erosion.